Transplant recipients invited to take part in new COVID-19 antibody study

January 18, 2022

If you have had a transplant, you’re aged 18 or over and have had (or are about to have) your third COVID-19 vaccine, you might like to consider taking part in a new study called the ‘Melody’ study.

What is the study about?

The national study will:

  1. Assess antibody responses after three COVID-19 vaccine doses in 36,000 immunocompromised people using a finger prick test that will be sent to your home.
  2. Investigate the correlation between antibodies after vaccination and the risk of infection over six months.
  3. Investigate what factors what factors are associated with immunocompromised people who don’t have an antibody response after vaccination eg, the type of medication you take. This will be determined by completing an online questionnaire with your antibody test results.

Why is the study needed?

We don’t know yet if having antibodies gives someone who is immunosuppressed long-lasting protection from the virus. The results of this study may help assess the impact of the vaccines on the level of antibody response to COVID-19 across the UK and help guide public health policy towards vulnerable groups.

How can I take part?

You will need your NHS/CHI number.

Step 1

Step 2

  • Antibody kit will be delivered to your house
  • You perform the antibody test

Step 3

  • Upload your results to the study portal
  • Answer a questionnaire about COVID-19

Who is running the study?

The study is being run by NHS Blood and Transplant, NHS Digital, and Ipsos MORI along with UK universities and charities.

To find out more about the study, you can read this patient information sheet PDF, go to: https://www.imperial.ac.uk/medicine/research-and-impact/groups/melody-study/ or call freephone 0800 819 9150.

More news

Our Budget Case to the Treasury: Investing in Prevention

Our Budget Case to the Treasury: Investing in Prevention

The Autumn Budget on 28th October is a chance to prevent thousands of families from experiencing the devastating impact of liver disease. Because 90% of liver disease is preventable, government action on alcohol harm and obesity could ...
Liver UK helps shape new European recommendations on liver cancer surveillance

Liver UK helps shape new European recommendations on liver cancer surveillance

A major new paper published in The Lancet Regional Health – Europe has highlighted the challenges of detecting liver cancer earlier across Europe and sets out practical lessons from countries around the world to improve surveillance ...
The LIVERAGE research studies

The LIVERAGE research studies

The LIVERAGE and LIVERAGE Cirrhosis studies are large clinical research studies for adults living with MASLD, a type of fatty liver disease. These studies focus on people with MASH, a more advanced form of MASLD.  The studies include ...
No results found.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.